EUVIMEDEUVIMED entdecken
EditorialKommentar

The limitations of persistence as a measure of efficacy of biologic therapies

Robert S Stern iD

British Journal of Dermatology · 16.11.2023 · 189 (6) · e100-e101

DOI: 10.1093/bjd/ljad322 ↗

Kurz gefasst

Editorial in der Zeitschrift British Journal of Dermatology, online erschienen am 06.09.2023. Verfasst von Robert S Stern. Beteiligte Einrichtung: Department of Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Psoriasis, Biological Products. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisBiological ProductsHumansCohort StudiesBiological FactorsBiological TherapyInsurance, Health

Substanzen

Biological FactorsBiological Products

Autor:innen und Institutionen

  • Department of Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

ORCID-Profile: Robert S Stern

Zitieren

APA

Stern, R. S. (2023). The limitations of persistence as a measure of efficacy of biologic therapies. British Journal of Dermatology, 189(6), e100-e101. https://doi.org/10.1093/bjd/ljad322

Vancouver

Stern RS. The limitations of persistence as a measure of efficacy of biologic therapies. British Journal of Dermatology. 2023;189(6):e100-e101. doi:10.1093/bjd/ljad322

BibTeX
@article{Stern2023,
  author = {Stern, Robert S},
  title = {The limitations of persistence as a measure of efficacy of biologic therapies},
  journal = {British Journal of Dermatology},
  year = {2023},
  volume = {189},
  number = {6},
  pages = {e100--e101},
  doi = {10.1093/bjd/ljad322}
}
Kostenlos starten →